InvestorsHub Logo
Followers 38
Posts 2971
Boards Moderated 0
Alias Born 10/07/2012

Re: itsabouttime post# 240325

Monday, 10/26/2015 2:45:15 PM

Monday, October 26, 2015 2:45:15 PM

Post# of 346073

A topline analysis revealed that treatment with KEYTRUDA was associated with longer overall survival (OS) compared with docetaxel treatment

Probably will be presented at a conference later would be my guess. Right now it is all about trying to keep up with Nivolumab.

As to actual #'s I doubt they are very different then what is known regarding Nivolumab and Docetaxel, or else they would have been screaming that from the rooftops.

Cheers.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News